Melatonin Levels in Smith Magenis Syndrome (SMS)

Stopped early · Not applicable

Conditions studied: Chromosome Disorders

In brief

The goal of this pilot project is to determine whether melatonin levels are disordered in patients with Smith-Magenis Syndrome (SMS) and whether melatonin treatment can correct abnormal circadian rhythms in SMS patients. In addition, the study investigates the effects of bright light in an elderly control population that exhibits low melatonin secretion.

Key facts

Study ID: NCT00691574
Run by: Oregon Health and Science University
People needed: 5
Starts: 1998-09-01
Expected to finish: 2009-05-01
Last updated by the study team: 2019-11-27

Who can join

Age: 3 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Control participants:
30 individuals: ages 55-85,
healthy without significant active medical problems.
SMS patients:
20 individuals: ages 3-50,
with a clinical diagnosis of Smith-Magenis Syndrome by a qualified Medical Geneticist, confirmed by cytogenetic analysis documenting deletion of chromosome band 17p11.2.

You may not qualify if…

Control participants:
A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual, abnormal heart, liver or kidney function, diagnoses of neurodegenerative or cerebrovascular disease (Alzheimer's disease, Parkinson's disease, stroke, etc.),
cognitive impairment (Mini-Mental State Score < 23) but without a formal diagnosis of dementia,
active symptoms of depression (Geriatric Depression Scale: 30 pt. version > 10),
current diagnosis of cataracts,
macular degeneration or retinopathy based on eye exam by an optometrist or ophthalmologist within the past year.

Where it is running

Sleep and Mood Disorders Lab, Oregon Health & Science University — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.